Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.480
+0.020 (0.81%)
Mar 6, 2026, 4:00 PM EST - Market closed
CNTB Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 0.76 | 26.03 | - | - | - | - | Upgrade
|
| Gross Profit | 0.76 | 26.03 | - | - | - | - | Upgrade
|
| Selling, General & Admin | 21.98 | 19.23 | 16.05 | 20.81 | 19.01 | 7.31 | Upgrade
|
| Research & Development | 34.15 | 29.26 | 53 | 96.63 | 80.5 | 23.12 | Upgrade
|
| Other Operating Expenses | - | - | - | -1.08 | -1.85 | -1.07 | Upgrade
|
| Operating Expenses | 56.13 | 48.49 | 69.06 | 116.36 | 97.66 | 29.36 | Upgrade
|
| Operating Income | -55.37 | -22.45 | -69.06 | -116.36 | -97.66 | -29.36 | Upgrade
|
| Interest Expense | - | - | - | -0.02 | -0.01 | -0.44 | Upgrade
|
| Interest & Investment Income | 2.73 | 4.45 | 5.22 | 1.81 | 0.17 | 0.21 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | 1.47 | -0.52 | -1.04 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.43 | 2.59 | 1.85 | - | -103.98 | -88.73 | Upgrade
|
| EBT Excluding Unusual Items | -52.2 | -15.41 | -61.99 | -113.1 | -202 | -119.36 | Upgrade
|
| Asset Writedown | - | - | - | -4.7 | - | - | Upgrade
|
| Pretax Income | -49 | -15.41 | -61.99 | -117.79 | -202 | -119.36 | Upgrade
|
| Income Tax Expense | 0.28 | 0.22 | 0.12 | 0.3 | 0.27 | - | Upgrade
|
| Earnings From Continuing Operations | -49.28 | -15.63 | -62.11 | -118.09 | -202.27 | -119.36 | Upgrade
|
| Net Income | -49.28 | -15.63 | -62.11 | -118.09 | -202.27 | -119.36 | Upgrade
|
| Net Income to Common | -49.28 | -15.63 | -62.11 | -118.09 | -202.27 | -119.36 | Upgrade
|
| Shares Outstanding (Basic) | 55 | 55 | 55 | 55 | 52 | 17 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 55 | 55 | 55 | 52 | 17 | Upgrade
|
| Shares Change (YoY) | 0.57% | 0.27% | 0.04% | 5.50% | 205.31% | 1.27% | Upgrade
|
| EPS (Basic) | -0.89 | -0.28 | -1.13 | -2.15 | -3.88 | -6.98 | Upgrade
|
| EPS (Diluted) | -0.89 | -0.28 | -1.13 | -2.15 | -3.88 | -6.98 | Upgrade
|
| Free Cash Flow | -43.01 | -24.36 | -47.82 | -105.93 | -88.16 | -27.9 | Upgrade
|
| Free Cash Flow Per Share | -0.78 | -0.44 | -0.87 | -1.92 | -1.69 | -1.63 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | - | - | - | - | Upgrade
|
| Operating Margin | -7266.01% | -86.24% | - | - | - | - | Upgrade
|
| Profit Margin | -6466.80% | -60.03% | - | - | - | - | Upgrade
|
| Free Cash Flow Margin | -5643.83% | -93.58% | - | - | - | - | Upgrade
|
| EBITDA | -54.69 | -21.79 | -68.34 | -115.63 | -97.17 | -29.21 | Upgrade
|
| EBITDA Margin | - | -83.71% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 0.68 | 0.66 | 0.72 | 0.73 | 0.49 | 0.15 | Upgrade
|
| EBIT | -55.37 | -22.45 | -69.06 | -116.36 | -97.66 | -29.36 | Upgrade
|
| EBIT Margin | - | -86.24% | - | - | - | - | Upgrade
|
| Revenue as Reported | 26.03 | 26.03 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.